Organ-specific pancreatic tumor growth properties and tumor immunity |
| |
Authors: | Keita Morikane Richard M Tempero Connie L Sivinski Mitsuharu Nomoto Michelle L Van Lith Tetsuichiro Muto Michael A Hollingsworth |
| |
Institution: | (1) Eppley Institute, University of Nebraska Medical Center, 600 South 42nd Street Omaha, NE 68198-6805, USA e-mail: mahollin@mail.unmc.edu Tel.: +1-402-559-8343; Fax: +1-402-559-4651, US;(2) Department of Surgery, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113, Japan, JP |
| |
Abstract: | We established a model of orthotopic injection of a syngeneic pancreatic tumor cell line in C57BL/6 mice and evaluated the
effects of organ site on induction of immunity to a tumor-specific antigen, MUC1. Mice were challenged with a syngeneic pancreatic
adenocarcinoma cell line that expressed MUC1 (Panc02-MUC1) by orthotopic injection into the pancreas, or by subcutaneous injection.
Tumor cells injected into the pancreas grew much faster than those injected subcutaneously. Mice challenged subcutaneously
with Panc02-MUC1 rejected tumors or developed slowly growing tumors that were negative for MUC1 expression. In contrast, mice
challenged orthotopically into the pancreas developed progressive tumors that were positive for MUC1 expression. Sera from
mice that rejected Panc02-MUC1 (tumor-immune mice) showed no detectable IgG1 and IgM titers against the MUC1 tandem-repeat
peptide, whereas mice with progressive tumor growth had significant titers of IgG1 and IgM specific for MUC1. This suggests
that the humoral immune response was ineffective in mediating tumor rejection. The results show that the growth properties
and immunological rejection of pancreatic tumors is affected by the organ site at which the tumor grows.
Received: 25 April 1998 / Accepted: 7 October 1998 |
| |
Keywords: | Pancreatic tumor Orthotopic injection MUC1 Tumor immunity Syngeneic |
本文献已被 PubMed SpringerLink 等数据库收录! |
|